Jazz Pharmaceuticals PLC (JAZZ)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 4,093,760 4,171,070 3,762,600 3,696,460 3,737,000 3,489,370 3,525,680 3,335,040 3,085,730 2,745,190 3,200,780 3,608,490 3,965,190 3,938,480 4,131,490 3,797,690 3,659,740 3,377,200 3,141,800 2,808,500
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $4,093,760K
= 0.00

The debt-to-equity ratio for Jazz Pharmaceuticals PLC has remained consistently at 0.00 across all reported periods from March 31, 2020, to December 31, 2024. This indicates that the company has been using little to no debt in comparison to equity to finance its operations and growth. A low or zero debt-to-equity ratio is generally viewed positively as it suggests lower financial risk and indicates that the company is not heavily reliant on borrowed funds for its business activities. However, while a low ratio can be beneficial, it may also suggest missed opportunities for leveraging debt to fund potential growth or expansion initiatives. Overall, with a consistent debt-to-equity ratio of 0.00, Jazz Pharmaceuticals PLC appears to have a strong financial position with a prudent capital structure.